-

Wugen to Present at the Innate Killer Summit 2022

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in a fireside chat and presentation at the Innate Killer Summit 2022 being held in San Diego, CA from Wednesday, March 30 – Friday, April 1, 2022.

The details of Wugen’s fireside chat and presentation are as follows:

  • Format: Industry Leader’s Fireside Chat
    Presenter: Dan Kemp, Ph.D., President and Chief Executive Officer, Wugen
    Date & Time: Thursday, March 31, 2022 at 8:15 a.m. PT
  • Format: Presentation titled “Characterizing an Ideal NK Cell Phenotype Leveraging Assays to Indicate Therapeutic Benefit”
    Presenter: Ayman Kabakibi, Ph.D., Chief Operating Officer & Executive Vice President, Research & Development, Wugen
    Date & Time: Thursday, March 31, 2022 at 11:30 a.m. PT

About WU-NK-101

WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.

Contacts

Investor Contact:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com

Industry:

Wugen, Inc.

Release Versions
English

Contacts

Investor Contact:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com

More News From Wugen, Inc.

Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented data for its two lead programs, WU-CART-007 and WU-NK-101, in separate presentations at the European Hematology Association (EHA) 2023 Congress, taking place from June 8 – 11, 2023 in Frankfurt, Germany. “We are very encouraged by these initial safety and efficacy data...

Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced an oral presentation and an onsite poster presentation highlighting data from Wugen’s WU-NK-101 and WU-CART-007 programs at the European Hematology Association (EHA) 2023 Congress, taking place from June 8 – 11, 2023 in Frankfurt, Germany. The oral presentation includes...

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the appointment of industry veteran Mark Alles as Chair of the Board of Directors. Mr. Alles is the former Chairman and Chief Executive Officer of Celgene Corporation. He has over 30 years of biopharmaceutical experience, and an outstanding record of driving growth a...
Back to Newsroom